Quark Venture, GF Securities invest $5 mln in Eloxx Pharma
Quark Venture and GF Securities Co Ltd have invested US$5 million in Eloxx Pharmaceuticals Ltd, a Rehovot, Israel clinical-stage company that is developing therapeutics to treat genetic diseases caused by non-sense mutations. The investment was part of a US$24 million Series C financing led by Pontifax Venture Capital. The funds raised will be used to initiate multiple clinical studies for the company's lead compound, ELX-02. Quark, a Canadian venture capital firm, and China's GF Securities are currently raising a US$500 million health sciences fund.
8 June 2017•4 mins read
